Alenezi Sattam Khulaif
Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, 51452, Al Qassim, Saudi Arabia.
Sci Rep. 2025 Jul 2;15(1):23356. doi: 10.1038/s41598-025-07181-5.
Huntington's Disease (HD), a neurodegenerative disease characterized by motor and cognitive impairments, arises from genetic mutations causing protein aggregation within the brain. The 3-Nitropropionic acid (3-NPA) rat model mimics key features of HD. This study explored the therapeutic efficacy of barbigerone, a compound with antioxidant and anti-inflammatory properties, in ameliorating 3-NPA-induced neurodegeneration and cognitive deficits in rats. Male Wistar rats were randomized into four groups: a normal control group, a 3-NPA control group, and two groups treated with different doses of barbigerone along with 3-NPA. Behavioral test, biochemical assays, and histopathological examinations were performed. Barbigerone significantly (P < 0.0001) restored motor coordination, grip strength, and mobility compared to 3-NPA-induced HD rats. Barbigerone concomitantly reduced oxidative stress by lowering malondialdehyde (MDA) and nitric oxide (NO) levels, while enhancing antioxidant enzymes such as glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT). Furthermore, treatment modulated the pro-inflammatory cytokines, suggesting a reduction in neuroinflammation. Barbigerone significantly (P < 0.0001) impacted changes in acetylcholinesterase (AChE) activity and modulated levels of key neurotransmitters, such as acetylcholine (ACh), norepinephrine (NE), serotonin (5-HT), gamma-aminobutyric acid (GABA), dopamine (DA), and glutamate (GLU). Additionally, barbigerone effectively attenuated the 3-NPA-induced elevation of caspase-3 and caspase-9, while upregulating brain-derived neurotrophic factor (BDNF), which is crucial for neuronal survival and cognitive function. Histopathological examination revealed that barbigerone significantly restored the altered striatal architecture, indicating a protective effect against neurodegeneration. Barbigerone exhibits potential as a therapeutic choice for HD, offering the possibility of alleviating motor impairments, oxidative stress, inflammation, and cognitive dysfunction.
亨廷顿舞蹈症(HD)是一种以运动和认知障碍为特征的神经退行性疾病,由基因突变导致大脑内蛋白质聚集引起。3-硝基丙酸(3-NPA)大鼠模型模拟了HD的关键特征。本研究探讨了具有抗氧化和抗炎特性的化合物巴比吉酮在改善3-NPA诱导的大鼠神经退行性变和认知缺陷方面的治疗效果。雄性Wistar大鼠被随机分为四组:正常对照组、3-NPA对照组以及两组分别用不同剂量巴比吉酮与3-NPA联合处理的组。进行了行为测试、生化分析和组织病理学检查(。与3-NPA诱导的HD大鼠相比,巴比吉酮显著(P < 0.0001)恢复了运动协调性、握力和活动能力。巴比吉酮同时通过降低丙二醛(MDA)和一氧化氮(NO)水平来减轻氧化应激,同时增强抗氧化酶如谷胱甘肽(GSH)、超氧化物歧化酶(SOD)和过氧化氢酶(CAT)。此外,治疗调节了促炎细胞因子,表明神经炎症有所减轻。巴比吉酮显著(P < 0.0001)影响乙酰胆碱酯酶(AChE)活性的变化,并调节关键神经递质的水平,如乙酰胆碱(ACh)、去甲肾上腺素(NE)、5-羟色胺(5-HT)、γ-氨基丁酸(GABA)、多巴胺(DA)和谷氨酸(GLU)。此外,巴比吉酮有效减弱了3-NPA诱导的半胱天冬酶-3和半胱天冬酶-9的升高,同时上调了对神经元存活和认知功能至关重要的脑源性神经营养因子(BDNF)。组织病理学检查显示,巴比吉酮显著恢复了纹状体结构的改变,表明对神经退行性变具有保护作用。巴比吉酮展现出作为HD治疗选择的潜力,为减轻运动障碍、氧化应激、炎症和认知功能障碍提供了可能性。